Gilliland Robertson H. 4
4 · ADIAL PHARMACEUTICALS, INC. · Filed Aug 2, 2018
Insider Transaction Report
Form 4
Gilliland Robertson H.
Director
Transactions
- Purchase
Warrant to purchase common stock
2018-07-31+14,000→ 43,931 total(indirect: By LLC)Exercise: $6.25From: 2018-07-31Exp: 2023-07-31→ Common Stock (43,931 underlying) - Conversion
Common Stock
2018-07-31+29,931→ 95,424 total(indirect: By LLC) - Purchase
Common Stock
2018-07-31+14,000→ 109,424 total(indirect: By LLC) - Conversion
Convertible Note
2018-07-31−29,931→ 0 total(indirect: By LLC)Exercise: $0.44→ Common Stock (29,931 underlying) - Conversion
Warrant to purchase common stock
2018-07-31+29,931→ 29,931 total(indirect: By LLC)Exercise: $6.25From: 2018-07-31Exp: 2023-07-31→ Common Stock (29,931 underlying)
Footnotes (3)
- [F1]The 29,931 shares of common stock and a warrant to purchase 29,931 shares of common stock were issued upon automatic conversion of a convertible note in the principal amount of $10,000 at a conversion price of $0.44 per share upon consummation of the initial public offering of the issuer on July 31, 2018.
- [F2]Mr. Gilliland is the principal of Keller Enterprises, LLC ("Keller").
- [F3]On July 31, 2018, Keller purchased 14,000 units (the "Units") in the initial public offering of the issuer at a price of $5.00 per Unit, which corresponds to a price of $4.99 per share of common stock and $0.01 per warrant. Each Unit consisted of one share of common stock and a warrant to purchase one share of common stock. The shares of common stock and warrants were immediately separable upon issuance of the Units in the IPO.